×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRNX – crinetics pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRNX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
09:00 am
crnx
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Medium
Report
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
11/14
04:17 pm
crnx
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting [Yahoo! Finance]
Medium
Report
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting [Yahoo! Finance]
11/14
04:05 pm
crnx
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Medium
Report
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
11/14
02:38 pm
crnx
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Citigroup Inc. from $70.00 to $74.00. They now have a "buy" rating on the stock.
Medium
Report
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Citigroup Inc. from $70.00 to $74.00. They now have a "buy" rating on the stock.
11/14
08:02 am
crnx
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) [Yahoo! Finance]
11/13
02:43 pm
crnx
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at HC Wainwright from $69.00 to $81.00. They now have a "buy" rating on the stock.
Low
Report
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at HC Wainwright from $69.00 to $81.00. They now have a "buy" rating on the stock.
11/13
02:26 am
crnx
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/12
04:08 pm
crnx
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:05 pm
crnx
crinetics pharmaceuticals, inc.
MISS
Report
0.2%
crinetics pharmaceuticals, inc.
8/8/2024
04:05 pm
crnx
crinetics pharmaceuticals, inc.
MISS
Report
-6.1%
crinetics pharmaceuticals, inc.
5/9/2024
04:05 pm
crnx
crinetics pharmaceuticals, inc.
MISS
Report
-1.8%
crinetics pharmaceuticals, inc.
2/28/2024
04:05 pm
crnx
crinetics pharmaceuticals, inc.
MISS
Report
-4.3%
crinetics pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
07:56 pm
crnx
Form SC 13G/A Crinetics Pharmaceutical Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SC 13G/A Crinetics Pharmaceutical Filed by: Point72 Asset Management, L.P.
11/14
05:47 pm
crnx
Form SC 13G/A Crinetics Pharmaceutical Filed by: EcoR1 Capital, LLC
High
Report
Form SC 13G/A Crinetics Pharmaceutical Filed by: EcoR1 Capital, LLC
11/14
01:24 pm
crnx
Form SC 13G Crinetics Pharmaceutical Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SC 13G Crinetics Pharmaceutical Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/12
04:16 pm
crnx
Form 10-Q Crinetics Pharmaceutical For: Sep 30
Low
Report
Form 10-Q Crinetics Pharmaceutical For: Sep 30
11/12
04:08 pm
crnx
Form 8-K Crinetics Pharmaceutical For: Nov 12
Low
Report
Form 8-K Crinetics Pharmaceutical For: Nov 12
11/12
02:26 pm
crnx
Form SC 13G/A Crinetics Pharmaceutical Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Crinetics Pharmaceutical Filed by: VANGUARD GROUP INC
11/8
10:53 am
crnx
Form SC 13G Crinetics Pharmaceutical Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G Crinetics Pharmaceutical Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/4
11:21 am
crnx
Form SC 13G/A Crinetics Pharmaceutical Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Crinetics Pharmaceutical Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
15.3%
4/4 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock. 11.0%
4/14 Form 424B5 Crinetics Pharmaceutical 7.6%
9/25 Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference 6.3%
1/8 Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 5.6%
8/7 Form 4 Crinetics Pharmaceutical For: Aug 05 Filed by: Struthers Richard Scott 5.5%
4/20 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.5%
3/4 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.9%
3/27 Form 3 Crinetics Pharmaceutical For: Mar 20 Filed by: Madan Ajay 4.1%
11/26 Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference 4.1%
4/4 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock. 11.0%
4/14 Form 424B5 Crinetics Pharmaceutical 7.6%
9/25 Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference 6.3%
1/8 Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 5.6%
8/7 Form 4 Crinetics Pharmaceutical For: Aug 05 Filed by: Struthers Richard Scott 5.5%
4/20 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.5%
3/4 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.9%
3/27 Form 3 Crinetics Pharmaceutical For: Mar 20 Filed by: Madan Ajay 4.1%
11/26 Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference 4.1%
TOP News Decliners
3/11
Form 4 Crinetics Pharmaceutical For: Mar 09 Filed by: Vivo Opportunity, LLC
-14.9%
4/6 Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update -10.9%
3/9 Q4/2019 12/31/2019 EPS -0.600 ZacksConsensus -0.670 ActVsEst 0.070 - Beat -9.4%
8/13 Q2/2019 6/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A -7.2%
7/29 Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism -5.7%
4/23 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.1%
2/25 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. -4.3%
1/11 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. -3.5%
2/26 Form 4 Crinetics Pharmaceutical For: Feb 24 Filed by: Struthers Richard Scott -3.2%
2/6 Form SC 13G/A Crinetics Pharmaceutical Filed by: 5AM Ventures IV, L.P. -2.8%
4/6 Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update -10.9%
3/9 Q4/2019 12/31/2019 EPS -0.600 ZacksConsensus -0.670 ActVsEst 0.070 - Beat -9.4%
8/13 Q2/2019 6/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A -7.2%
7/29 Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism -5.7%
4/23 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.1%
2/25 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. -4.3%
1/11 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. -3.5%
2/26 Form 4 Crinetics Pharmaceutical For: Feb 24 Filed by: Struthers Richard Scott -3.2%
2/6 Form SC 13G/A Crinetics Pharmaceutical Filed by: 5AM Ventures IV, L.P. -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: